Amber McDonald
Pulmonary Disease · Las Vegas, NVNPI 1588191936
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,615 of the $3,252 with a category attached, or 80.4%. 18 manufacturers reported payments, led by Intuitive Surgical at 48.4% of the total. Reporting peaked in 2021 at $993 and has fallen 85.8% since, to $141 in 2025.
Across 37 payments — averaging $87.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$2K
- Atricure, Inc.$468
- Davol Inc.$183
- AstraZeneca$145
- Mylan Specialty L.p.$141
- Novo Nordisk$139
- plus $602 from 12 others
What the payments were for
- Travel & lodging$63720%
- Food & beverage$2,61580%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 11 | $1,574 |
| Atricure, Inc. | 3 | $468 |
| Davol Inc. | 2 | $183 |
| AstraZeneca | 2 | $145 |
| Mylan Specialty L.p. | 2 | $141 |
| Novo Nordisk | 2 | $139 |
| Amarin Pharma, Inc. | 2 | $139 |
| Pulmonx Corporation | 1 | $132 |
| Fisher & Paykel Healthcare Inc | 1 | $102 |
| Lilly USA, LLC | 2 | $90 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Viz.ai, Inc. | 1 | $20 |
| Sanofi | 1 | $18 |
| Bayer | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
| Pfizer | 1 | $14 |
| Nalpropion Pharmaceuticals LLC | 1 | $13 |
| Tandem Diabetes Care, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,252 in reported general payments places this provider in the 65th percentile of 84 pulmonary disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Las Vegas
- Arthur RomeroLas Vegas$310K
- Lloyd DelmundoLas Vegas$150K
- Naresh SinghLas Vegas$111K
- Abhishek KumarLas Vegas$74K
- Jerome HruskaLas Vegas$72K
- Vishisht MehtaLas Vegas$22K
- Kamran KhanLas Vegas$17K
- John WojcikLas Vegas$14K
- Walter WilloughbyLas Vegas$10K
- Robert LampertLas Vegas$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.